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TNF-alpha blockers represent one of the most important therapeutic strategies for rheumatoid arthritis, but their use has raised
thequestion about their safety proﬁle, particularly in respect toviral infections/reactivations. We describethecaseof a patient who
developed a symptomatic EBV reactivation 11 days after the ﬁrst infusion of inﬂiximab.
1.Introduction
Rheumatoid arthritis (RA) is a chronic disease characterized




response, in which some cytokines, such as tumor necrosis
factor- (TNF-) alpha, interleukin 1 and 6, play a pivotal role.
Therefore, the development and the use of biologic agents,
mainly the TNF-alpha blockers, represents one of the most
important therapeutic strategies to treat RA patients nonre-
sponder to traditional disease-modifying agents (DMARDs)
[1].
In fact, TNF-alpha blockers have unequivocally demon-
strated their eﬃcacy in reducing disease activity and in de-
creasing the probability of articular damage, especially in
association to methotrexate [1]. The widespread use of TNF-
alpha blockers has raised the question about their safety
proﬁle; in fact, it has been well recognized that these biologic
agents interfere with a number of immune defense path-
ways, particularly those correlated with the response against
intracellular microbes [2].
The data from clinical trials and from safety registries
have identiﬁed an increased risk for certain infections, ﬁrst
of all Tuberculosis [3]. Moreover, the risk of reactivation
of certain viruses, including Epstein-Barr virus (EBV), has
been suspected in patients treated with TNF-alpha blockers,
and it has been clearly shown in transplant recipients and
otherimmunosuppressedsubjects[4].Recently,afewstudies
have been published in order to investigate this hypothesis,
concluding that TNF-alpha blockers have only a minimal, if
any, inﬂuence on latent viral replication [5–9].
Here, a case of symptomatic EBV reactivation in a RA
patient treated with inﬂiximab is described.
2.CaseReport
B.M., a 20-years-old female was referred to our Rheumato-
logic Clinic in March2009 foran overtarthritis involving the
third proximal interphalangeal (PIP) joint of the left hand
and the ﬁrst metacarpophalangeal (MCP) joint of the right
hand.Besidearthritis,whichappearedsixmonthsbefore,the
patient presented fatigue, morning joint stiﬀness for about
three hours, and more recently pain also in the wrists and in
the other MCP and PIP joints. At the physical examination,
both the knees and wrists were swollen, together with the
ﬁrstlyinvolvedjoints.Laboratorytestsshowedslightincrease
of erythrocyte sedimentation rate (24mmh) and c-reactive
protein 1.4mg/dL, presence of serum rheumatoid factor
(182UI/mL; n.v. < 14), anticitrullinated peptide antibodies
(251.6UI/mL; n.v. < 25), while antinuclear antibodies were
negative. Firstly, in the hypothesis of reactive arthritis
because of a transient genital infection by Ureaplasma
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Figure 1: The rash present on the patient’s trunk 11 days after the
inﬂiximab infusion.
administered for about three months; but, arthritis did not
show any signiﬁcant improvement. Radiograms of the hands
evidencedtypicalmarginalerosionatthebasisofthephalanx
of the third PIP joint. On these basis, a diagnosis of early RA
was made, and a treatment with methotrexate 10mg/week
plus prednisone 5mg/day and diclofenac 150mg/day was
started.
In the following 3 months, the patient did not experience
a signiﬁcant improvement of her symptoms, so she contin-
ued to take diclofenac every day. Similarly, leﬂunomide
20mg/day in association with diclofenac and steroids did
not show satisfying results. After a negative screening for
hepatitis B and C virus and Mycobacterium tuberculosis, a
treatment with inﬂiximab 3mg/kg was decided, considering
theactivityandtheseverityofarthritis.Theﬁrstinfusionwas
performed on 15th October 2009, without steroid or antihis-
taminic premedication; no adverse reactions were registered
during the infusion and in the following week. On 26th
October, the patient presented a macular rash on the neck
and the trunk (Figure 1), and painful lymphonodes behind
theearsandontheneck;feverof37.5◦Candsorethroatwere
also present.
Suspecting a viral infection, a serological evaluation for
measles,EBV,Cytomegalovirus,andParvovirusB19wasper-
formed, using an immunoenzymatic reaction kit (Techno-
genetics-Bouty, Milan, Italy). EBV-VCA IgM resulted 2.01
(values > 1.10 were considered positive), EBV-VCA IgG 121
(values > 11.5 were considered positive), along with serum
EBV-EBNA IgG (memory antibodies). The IgM antibodies
directed against the other investigated viruses were negative.
All the above symptoms disappeared in ﬁve days spon-
taneously and did not reappear up to date. In the same
time, arthritis dramatically improved after the ﬁrst infusion
of inﬂiximab, with apparent resolution of synovitis of
the wrists, knees, and hands. The second inﬂiximab infusion
was done one month later, after the complete resolution of
the EBV reactivation symptoms.
3. Discussion
T h ec a s eh e r ed e s c r i b e dr e p r e s e n t sav i r a lr e a c t i v a t i o nc o m -
plicatingTNF-alphablockertreatment.EBVreactivationwas
clinicallysuspectedbecauseoftheappearanceoffever,macu-
lar rash, pharyngitis, and lymphoadenopathies. It was con-
ﬁrmed by the presence of EBV-VCA IgM antibodies in the
serum,whereastheEBV-EBNAIgGantibodiesdemonstrated
a previous contact with the virus. A previous positivity of
EBV-VCA IgM cannot be deﬁnitely excluded; however, the
patient’s clinical picture is reasonably suggestive of EBV re-
activation.
SeveralstudieshaveinvestigatedthepossibilityofanEBV
reactivation in patients treated with inﬂiximab, showing no
signiﬁcant increased risk [5–8]. In a study of 60 patients with
Crohn’s disease treated with inﬂiximab, none showed EBV
viremia or any clinical manifestation of EBV infection after
the treatment [6]. In addition, no signiﬁcant modiﬁcations
of EBV serological markers were demonstrated in a series of
68RApatientstreatedwithinﬂiximaband48withetanercept
[7]. Finally, serum EBV DNA was never found in a series
of anti-EBV IgG-positive patients treated with TNF-alpha
blockers [8], while the EBV viral load and the number of
IFNγ-producing T cells after viral peptide stimulation were
not signiﬁcantly increased after TNF-alpha blockers in
patients with RA or spondylarthropathy [9].
Ontheotherhand,Komatsudaetal.describedthecaseof
a RA patient who developed a Hodgkin-like lymphoprolifer-
ativedisorder,relatedtoEBV,atthe30thmonthofinﬂiximab
treatment, which dramatically regressed after anti-TNF-
alpha discontinuation [10]. Indeed, it has been observed that
the immune response to EBV is slightly impaired in RA
patients [11]; consequently, this possible ineﬃcient control
of the virus might be exalted by the treatment with TNF-
alpha blockers in a few RA patients.
Itispresumablethattheviralreactivationmightbearare
event, which is diﬃcult to verify in the relatively small series
of patients previously investigated [5–9]. Moreover, it is also
possible that this event may be misdiagnosed or entirely
overlooked because it could be characterized by nonspeciﬁc,
often mild clinical manifestations. In our case, the clinical
picture was quite relevant to suspect the diagnosis, even
though it was transient and substantially did not inﬂuence
the inﬂiximab schedule and therapeutic response. In general,
we cannot exclude the fact that apparently benign EBV
reactivation might trigger more serious complications due to
the potential EBV-driven autoimmune-lymphoproliferative
phenomena, particularly in genetically predisposed patients.
Further studies could clarify if EBV serological evaluations
should be included in the screening before anti-TNF-alpha
therapy.
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